Enhancing the ability of T cells to control HIV after treatment
Targeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIV
This study is looking at how to boost certain T cells in people with HIV so they can better fight the virus after stopping their medication, with the hope of finding new ways to help manage the virus in the long run.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10999460 on NIH RePORTER |
What this research studies
This research investigates how specific types of T cells can be enhanced to better control HIV after patients stop their antiretroviral therapy. The approach focuses on understanding the characteristics of T cells that can resist exhaustion and effectively target HIV-infected cells. By studying these T cells in mouse models, researchers aim to identify the best strategies for improving T cell responses in individuals living with HIV. The goal is to develop therapies that could lead to better long-term control of the virus.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have undergone antiretroviral therapy and are interested in exploring new treatment options.
Not a fit: Patients who are not living with HIV or those who have not received antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies that help patients maintain control of HIV without the need for continuous medication.
How similar studies have performed: Previous research has shown promise in using T cell therapies for cancer, suggesting that similar approaches may be effective for HIV, although this specific application is still being explored.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Rutishauser, Rachel Lena — University of California, San Francisco
- Study coordinator: Rutishauser, Rachel Lena
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.